DelveInsight’s “Biliary Tract Cancer Market Insights, Epidemiology, and Market Forecast-2036” report delivers an in-depth understanding of Biliary Tract Cancer, historical and forecasted epidemiology, as well as the Biliary Tract Cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France), and Japan.

Discover Key Insights into the Biliary Tract Cancer Market with DelveInsight’s In-Depth Report @ Biliary Tract Cancer Market Size

Key Takeaways from the Biliary Tract Cancer Market Report

• In January 2026, TransThera Sciences announced presentation of tinengotinib monotherapy in patients with advanced cholangiocarcinoma at American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) 2026.

• According to DelveInsight’s estimates, in 2025, Japan recorded the highest number of incident cases of BTC in the 7MM at approximately 22,000 cases, which are expected to continue increasing at a CAGR of 1.2%.

• In the 7MM, durvalumab (IMFINZI) holds the largest market share in 2025, generating approximately USD 330 million, followed by Pemigatinib (PEMAZYRE).

• In the US, the 65+ age group accounted for approximately 65% of BTC cases in 2025.

• Intrahepatic cholangiocarcinoma (iCCA) has shown a rising incidence trend in Western countries, with Europe experiencing approximately 15-20% annual growth in diagnosis rates.

• The global BTC market is expected to reach USD 4.2 Billion by 2036, driven by expansion of targeted therapies and increased adoption of precision medicine.

• Biomarker testing adoption is projected to increase from current 35% to over 75% by 2030 across the 7MM, significantly influencing treatment selection and market dynamics.

• Combination therapies are anticipated to account for approximately 60% of the BTC market by 2036, up from 40% in 2025.

• The leading Biliary Tract Cancer companies such as AstraZeneca, Merck & Co., Compass Therapeutics, Incyte, Roche/Genentech, Bayer, and others.

• Promising Biliary Tract Cancer Therapies such as Ivosidenib, Pemigatinib, Rilvegostomig, Tinengotinib, Tovecimig, Nanvuranlat, and others.

Stay ahead in the Biliary Tract Cancer Therapeutics Market with DelveInsight’s Strategic Report @ Biliary Tract Cancer Market Outlook

Biliary Tract Cancer Epidemiology Segmentation in the 7MM

• Patient Burden Assessment

• Total Biliary Tract Cancer Incident Cases

• Cholangiocarcinoma Primary Incident Cases

• Gallbladder Cancer Incident Cases

• Ampullary Carcinoma Incident Cases

• Age-specific Incident Cases of Biliary Tract Cancer

• Gender-based Incident Cases of Biliary Tract Cancer

• Mutation-specific Incident Cases of Biliary Tract Cancer (FGFR2, IDH1, BRAF V600E, NTRK, HER2, MSI-H)

• Stage-specific Incident Cases of Biliary Tract Cancer (Localized, Locally Advanced, Metastatic)

• Risk Factor-based Segmentation (Chronic Liver Disease, Bile Duct Inflammation, Infections, Genetic Predisposition)

Download the report to understand which factors are driving Biliary Tract Cancer epidemiology trends @ Biliary Tract Cancer Prevalence

Biliary Tract Cancer Pipeline Analysis

• Pemigatinib (PEMAZYRE): Incyte

Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. This therapy demonstrates strong efficacy in FGFR2-rearranged cholangiocarcinoma and holds the second-largest market share in the 7MM. Patent protection is expected through 2035-2040.

• Ivosidenib (TIBSOVO): Agios Pharmaceuticals/Servier Pharmaceuticals

Ivosidenib is an isocitrate dehydrogenase 1 (IDH1) inhibitor approved for the treatment of cholangiocarcinoma with an IDH1 mutation. It became the first IDH1 inhibitor approved for BTC, targeting approximately 15–20% of cholangiocarcinomas harboring IDH1 mutations, representing a significant therapeutic breakthrough in precision oncology for BTC. Recent Phase III data demonstrates overall response rates exceeding 26% in IDH1-mutant populations.

• Rilvegostomig (AZD2936): AstraZeneca

Rilvegostomig is a first-in-class dual-checkpoint bispecific antibody providing PD-1 and TIGIT blockade on the same immune cell to restore antitumor immunity and enable durable responses. This emerging therapy represents a novel approach in the treatment of immune-resistant Biliary Tract Cancer. Expected US launch targeted for 2030 in first-line settings, with potential peak sales projection of USD 480 million annually.

• Tinengotinib (TT-00420): TransThera Sciences

Tinengotinib is an investigational oral multi-kinase inhibitor for cholangiocarcinoma, especially in patients with FGFR-altered tumors who progressed after prior therapy. It targets FGFR1–3, VEGFR, Aurora, and JAK kinases, with data recently presented at ASCO GI 2026 and a US launch anticipated in 2027. Preliminary efficacy data shows an overall response rate of approximately 32% in FGFR-altered populations.

• Tovecimig (CTX-009): Compass Therapeutics

Tovecimig is a bispecific antibody targeting DLL4 and VEGF-A pathways to inhibit complementary angiogenic mechanisms in advanced BTC. Currently in Phase II/III development, this therapy addresses the hypoxic and angiogenesis-dependent nature of cholangiocarcinomas. Anticipated launch window is 2028-2029 with peak sales projections of USD 350 million.

• Nanvuranlat (JPH203): J-Pharma/OHARA Pharmaceutical

Nanvuranlat is a novel L-type amino acid transporter (LAT1) inhibitor currently in Phase III trials for advanced BTC. This represents a unique mechanistic approach targeting tumor-dependent amino acid metabolism, addressing an unmet therapeutic need. Site activation for the global Beacon-BTC Phase III trial was completed in December 2025, with anticipated regulatory decision by 2028.

Biliary Tract Cancer Drugs Market Insights

Novel targeted therapies and immunotherapies are transforming the treatment landscape of Biliary Tract Cancer. FGFR inhibitors, such as pemigatinib and futibatinib, have expanded treatment options for FGFR2-fusion-positive cholangiocarcinoma with response rates approaching 30%. IDH1 inhibitors, including ivosidenib, are showing promise for IDH1-mutated disease with durable responses extending beyond 12 months in responder populations.

Bispecific antibodies like rilvegostomig and tovecimig are being explored to overcome the immune-resistant nature of BTC through dual immune checkpoint blockade and anti-angiogenic pathways. Emerging LAT1 inhibitors represent a novel class targeting metabolic dependencies in cholangiocarcinoma cells. Multi-kinase inhibitors targeting VEGFR, JAK, and other pathways continue to demonstrate therapeutic potential with synergistic effects in combination regimens.

The integration of immunotherapy with standard chemotherapy has marked the most significant paradigm shift in first-line therapy for BTC, with combination approaches demonstrating 15-20% improvement in overall survival compared to chemotherapy alone. Liquid biopsy technologies and circulating tumor DNA monitoring are increasingly being integrated into clinical practice, enabling real-time treatment response assessment and early detection of resistance mechanisms, expected to improve treatment outcomes by 25-30% by 2030.

Cell-surface antigen targeting through CAR-T cell therapy approaches for BTC-specific antigens are currently in preclinical development, with Phase I trials anticipated to initiate by 2027. Additionally, small molecule inhibitors targeting the Wnt/β-catenin pathway are showing preliminary efficacy in preclinical models of BTC stem cells, representing a potential avenue for addressing treatment-resistant populations.

Get In-Depth Knowledge on Biliary Tract Cancer Market Trends and Forecasts with DelveInsight @ Biliary Tract Cancer Treatment Market

Biliary Tract Cancer Market Outlook

Biliary Tract Cancer represents a rare but highly lethal group of malignancies with an overall 5-year survival rate of approximately 15%, dropping to 8.5% for intrahepatic cholangiocarcinoma, particularly in patients with metastatic disease. However, outcomes in biomarker-selected populations receiving targeted therapies demonstrate significantly improved progression-free survival rates of 8-12 months compared to 4-6 months with chemotherapy alone. Curative treatment relies on surgical resection, with chemotherapy serving as the primary systemic therapy for advanced or unresectable disease. Platinum-based combination chemotherapy has historically served as the backbone of systemic therapy in advanced or unresectable disease across the 7MM.

Recent regulatory approvals have significantly expanded treatment options. The approval of durvalumab in combination with gemcitabine and cisplatin for first-line treatment of locally advanced or metastatic BTC marked the first immunotherapy-based regimen approved in the frontline setting, with initial 2-year follow-up data demonstrating durable remissions in 22% of treated patients. The market is experiencing a paradigm shift from a “one-size-fits-all” chemotherapy approach to a highly segmented, biomarker-driven landscape, with targeted therapies addressing molecular alterations including FGFR2 fusions (detected in 10-15% of cases), IDH1 mutations (15-20%), BRAF V600E (5-7%), NTRK fusions (1-2%), HER2 amplification (3-5%), and MSI-H (2-3%).

The adoption of next-generation sequencing (NGS) for comprehensive genomic profiling is accelerating, with approximately 45% of treatment-naïve BTC patients currently undergoing molecular testing, expected to reach 75% by 2030. This expansion will unlock access to targeted therapies for additional patient populations and enable development of novel biomarker combinations.

Despite recent therapeutic advances, critical unmet needs remain, including the absence of reliable, non-invasive biomarkers for early detection with sensitivity >85% and specificity >90%, and the lack of predictive markers accurately identifying patients with durable immunotherapy response. Current clinical response prediction models achieve only 60% accuracy, necessitating development of improved multi-omics biomarker panels. Additionally, the development of strategies to overcome acquired resistance to FGFR inhibitors, observed in approximately 30-40% of patients after 12-18 months of treatment, remains a critical priority. Geographic disparities in treatment access, particularly in resource-limited regions where BTC incidence is highest, underscore the need for more affordable therapeutic options and improved healthcare infrastructure.

Scope of the Biliary Tract Cancer Market Report

• Coverage- 7MM

• Study Period- 2020-2034

• Forecast Period- 2024-2036

• Historical Market Size Analysis and Forecasted Market Growth (2022-2036)

• Biliary Tract Cancer Companies- AstraZeneca, Merck & Co., Compass Therapeutics, Incyte, Roche/Genentech, Bayer, Eisai, Seagen, and others.

• Biliary Tract Cancer Therapies- Ivosidenib, Pemigatinib, Rilvegostomig, Tinengotinib, Tovecimig, Nanvuranlat, Futibatinib, Durvalumab, and others.

• Biliary Tract Cancer Market Access & Reimbursements, Unmet Needs and Perspectives

• Biomarker Testing Adoption Rates and Impact on Market Dynamics

• Real-World Evidence and Treatment Pattern Analysis

• Pricing and Reimbursement Scenario Across Different Healthcare Systems

• Biliary Tract Cancer SWOT Analysis and KOL Views

• Competitive Landscape and Market Share Projections

• Pipeline Analysis with Phase-Specific Breakdown and Probability of Success Estimations

Unlock Strategic Insights with DelveInsight’s Comprehensive Biliary Tract Cancer Market Report @ Biliary Tract Cancer Market Drivers and Barriers

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. Biliary Tract Cancer (BTC) Market Overview at a Glance

7. Disease Background and Overview of Biliary Tract Cancer (BTC)

8. Epidemiology and Patient Population of Biliary Tract Cancer (BTC)

9. Patient Journey of Biliary Tract Cancer (BTC)

10. Marketed Therapies of Biliary Tract Cancer (BTC)

11. Emerging Therapies of Biliary Tract Cancer (BTC)

12. Biliary Tract Cancer (BTC): 7MM Analysis

13. Unmet Needs of Biliary Tract Cancer (BTC)

14. SWOT Analysis of Biliary Tract Cancer (BTC)

15. KOL Views of Biliary Tract Cancer (BTC)

16. Market Access and Reimbursement of Biliary Tract Cancer (BTC)

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/